Leerink Partnrs Has Negative Outlook of VKTX FY2025 Earnings
Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...
Tourmaline Bio FY2024 EPS Forecast Raised by Leerink Partnrs
Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...
T-knife Therapeutics to Participate in Two Investor Conferences in March
SAN FRANCISCO and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer ...
Modern Healthcare3h
CVS soars after Q4 profit signals improvement
Adjusted earnings for 2025 will be $5.75 to $6 a share, CVS said, while the average estimate of analysts surveyed by ...
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Arvinas Holding Company (ARVN) and Accolade (ACCD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edwards Lifesciences (EW – Research Report), Arvinas Holding ...
Fintel on MSN4d
Leerink Partners Upgrades Doximity (DOCS)
Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...
Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...
Ex-Goldman Banker Advances Some Pay Claims Against Leerink Firm
An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...
Nasdaq14d
Leerink Partners Upgrades Doximity (DOCS)
Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform to Outperform. As of January 29, 2025, the average one-year price ...